🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A pre-infusion inflammation biomarker signature predicts treatment failure in non-Hodgkin lymphoma patients treated with CAR T cell therapy, with inflammatory cluster assignment indicating clinical response and survival outcomes. Sandeep Raj Roni Shouval nature.com/articles/s4159…

1/ Why do late-stage cancer patients lose motivation & sink into apathy? 🔥Our new Science paper shows cancer activates a cytokine-sensing brain circuit to lower motivation.Great work by Aelita Zhu Sarah Starosta Marco Pignatelli Tobias Janowitz &team!🧵 🔗 doi.org/10.1126/scienc…

Excited to share our review on CAR arming of the innate immune cells. Engineering innate immune cells for cancer immunotherapy | Nature Biotechnology nature.com/articles/s4158…

🚨 Check out our new grading system for thrombocytopenia (#T_ICAHT) after #CART doi.org/10.1182/blood.… Blood Journal Led by Drs. Kai Rejeski, Jaime Sanz, Teng Fei & team — incredible multicenter collaborative effort. See Kai’s 🧵for more insights!

Another good example of utilizing the powerful {gtsummary}, {ggsurvfit} and {tidycmprsk} packages for clinical data analysis Memorial Sloan Kettering Biostatistics Service. Congratulations to Kai Rejeski, Jaime, Roni Shouval, and team!

Congrats to Kai Rejeski, Roni Shouval, and their team on developing a new grading system to evaluate patterns of thrombocytopenia in patients treated with commercial CD19 CAR-T therapy for B-cell non-Hodgkin #lymphoma. @BloodJournal Read the study: bit.ly/42FHRgd

🚨New milestone for #CARTcell therapy in #GlobalHematology! We report the first successful decentralized, academic-grade CD19 CAR-T manufacturing in healthy donors in Mexico 🇲🇽 and half a dream come true. 📄 JCO Global Oncology: ascopubs.org/doi/10.1200/GO… 1/🧵👇

Combined #preprint and paper alert! Together with Sohrab Shah and Vivian E. Strong, MD, we have been exploring a fundamental paradox of cancer biology: how can the immune response both suppress and facilitate tumorigenesis? (It's a 2-parter!) biorxiv.org/content/10.110…

📢 New Review Out in Haematologica! Together with Ofrat Beyar Katz and Kai Rejeski, we discuss hematologic toxicities of CAR-T therapy—definitions, mechanisms, and clinical impact. Read the full review 👉 haematologica.org/article/view/1… #CAR_T #Hematology #Toxicity

Phenomenal work by Alejandro Luna. Grateful to IACH for highlighting our study. Read more nature.com/articles/s4140… Blood Cancer Journal.

We previously showed that IFNg is required for CAR-T efficacy in solid tumors, but is it always good? Here, we show that IFNg limits CD28 CAR-T cells and that protection from this signal drives greater antitumor activity and durability. Enjoy! science.org/doi/10.1126/sc…

🎉Finally out🎉 Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma Now in Blood Journals Portfolio Timely for #EHA2025🥰 #mmsm ashpublications.org/blood/article/…